Company: VRCA
Filing Date: 2025-12-23
Form Type: 424B3
Source: 0001193125-25-330986
Chunk: 13

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-12-23
Form: 424B3
Chunk 13
---
 beneficially own the shares beneficially owned by Velan. The address of Velan is 100 North Main Street, Suite 301, Alpharetta, 
 Georgia, 30009.                                                                                                                                                                                                                                       |

| (13) | “Beneficial Ownership Prior to this Offering” consists of (a) 353,669 shares of our common stock                                                                                                                                             
 issued to Stonepine Capital, LP (“Stonepine”) in the Private Placement and (b) 88,417 shares of our common stock issuable upon exercise of Common Warrants issued to Stonepine in the Private Placement. Jon M. Plexico exercises voting and 
 investment discretion with respect to these securities and as such may be deemed to beneficially own the shares held by Stonepine. The address of these funds and persons is 2900 NW Clearwater Drive, Ste                                   
 100-11, Bend, Oregon 97703.                                                                                                                                                                                                                  |

| (14) | “Beneficial Ownership Prior to this Offering” consists of (a) 157,972 shares of our common stock                                                                                                                                                       
 issued to DAFNA Lifescience L.P. (“DAFNA”) in the Private Placement, (b) 77,807 shares of our common stock issued to DAFNA Lifescience Select L.P. (“DAFNA Select”) in the Private Placement, (c) 39,493 shares of our common                          
 stock issuable upon exercise of Common Warrants issued to DAFNA in the Private Placement and (d) 19,451 shares of our common stock issuable upon exercise of Common Warrants issued to DAFNA Select in the Private Placement. DAFNA Capital Management 
 LLC is the sole general partner of DAFNA and DAFNA Select. The Chief Executive Officer and Chief Investment Officer of DAFNA Capital Management LLC are Dr. Nathan Fischel and Dr. Fariba Ghodsian, respectively. These individuals may be             
 deemed to have shared voting and investment power of the shares held by DAFNA and DAFNA Select. The address for the entities and individuals herein is 10990 Wilshire Blvd, Suite 1400, Los Angeles, California 90024.                                 |

| (15) | “Beneficial Ownership Prior to this Offering” consists of (a) 235,779 shares of our common stock                                                                                                                                          
 issued to Kalehua Capital Partners LP (“Kalehua”) in the Private Placement and (b) 58,944 shares of our common stock issuable upon exercise of Common